Treatment of estrogen receptor-positive breast cancer

Current Medicinal Chemistry

Volumn 20, Issue 5, 2013, Pages 596-604

  Lumachi, F ^a   Brunello, A ^b   Maruzzo, M ^b   Basso, U ^b   Basso, S M M ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Aromatase inhibitors; Breast cancer; Estrogen receptor; Ovary suppression; SERD; SERM; Tamoxifen

Indexed keywords

ANASTROZOLE; CITALOPRAM; ESTROGEN RECEPTOR; EXAMESTANE; FULVESTRANT; LETROZOLE; RALOXIFENE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ARTICLE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER RISK; CARDIOVASCULAR RISK; DOWN REGULATION; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FRACTURE; HUMAN; OVARY FUNCTION; VEIN THROMBOSIS;

EID: 84877944012     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804999303     Document Type: Article

References (121)

1. Siegel, R.; DeSantis, C.; Virgo, K.; Stein, K.; Mariotto, A.; Smith, T.; Cooper, D.; Gansler, T.; Lerro, C.; Fedewa, S.; Lin, C.; Leach, C.; Cannady, R.S.; Cho, H.; Scoppa, S.; Hachey, M.; Kirch, R.; Jemal, A.; Ward, E. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin., 2012, 62, 220-241.
2. World Health Organization. Breast Cancer. In: World Cancer Report; Stewart, B.W.; Klihuses, P., Eds.; IARC Press: Lyon, 2003, pp. 188-193.
3. Gonzalez-Angulo, A.M.; Morales-Vasquez, F.; Hortobagyi, G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Mol., 2007, 608, 1-22.
4. Lumachi, F.; Luisetto, G.; Basso, S.M.M.; Basso, U.; Brunello, A.; Camozzi, V. Endocrine therapy of breast cancer. Curr. Med. Chem., 2011, 18, 513-522.
5. Wright, T.; McGechan, A. Breast cancer: new technologies for risk assessment and diagnosis. Mol. Diagn., 2003, 7, 49-55.
6. Gerrero, M.R.; Weber, B.L. Recent advances in breast cancer biology. Curr. Opin. Oncol., 2001, 13, 415-449.
7. Masood, S. Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn. Cytopathol., 1992, 8, 475-491.
8. Mohibi, S.; Mizra, S.; Band, H.; Band, V. Mouse models of estrogen receptor-positive breast cancer. J. Carcinog., 2011, 10, 35.
9. Martin, M. Molecular biology of breast cancer. Clin. Transl. On col., 2006, 8, 7-14.
10. Ross, J.S.; Fletcher, J.A.; Bloom, K.J.; Linette, G.P.; Stec, J.; Symmans, W.F. Pusztai, L.; Hortobagyi, G.N. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell. Proteomics, 2004, 3, 379-398.
11. Navolanic, P. M.; Steelman, L.S.; McCubrey, J. A. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int. J. Oncol., 2003, 22, 237-252.
12. Lim, E.; Metzger-Filho, O.; Winer, E.P. The natural history of hormone receptor-positive breast cancer. Oncology, 2012, 26, 688-694.
13. Tsai, M.J.; O. Malley, B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem., 1994, 63, 451-486.
14. Millikan, R.C.; Newman, B.; Tse, C.K.; Moorman, P.G.; Conway, K.; Dressler, L.G.; Smith, L.V.; Labbok, M.H.; Geradts, J.; Bensen, J.T.; Jackson, S; Nyante, S.; Livasy, C.; Carey, L.; Earp, H.S.; Perou, C.M. Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat., 2008, 109, 123-139.
15. Malhotra, G.K.; Zhao, X.; Band, H.; Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol. Ther., 2010, 10, 955-960.
16. Nielsen, T.O.; Hsu, F.D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; Akslen, L.A.; Ragaz, J.; Gown, A.M.; Gilks, C.B.; van de Rijn, M.; Perou, C.M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res., 2004, 10, 5367-5374.
17. Goldhirsch, A.; Wood, W.C.; Coates, A.S.; Gelber, R.D.; Thürlimann, B.; Senn, H.J. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol., 2011, 22, 1736-1747.
18. de Azambuja, E.; Cardoso, F.; de Castro, G. jr.; Colozza, M.; Mano, M.S.; Durbecq, V.; Sotiriou, C.; Larsimont, D; Piccart-Gebhart, M.J.; Paesmans, M. Ki-67 as prognostic marker in early breast cancer: a meta-Analysis of published studies involving 12,155 patients. Br. J. Cancer, 2007, 96, 1504-1513.
19. Cheang, M.C.; Chia, S.K.; Voduc, D.; Gao, D.; Leung, S.; Snider, J.; Watson, M.; Davies, S.; Bernard, P.S.; Parker, J.S.; Perou, C.M.; Ellis, M.J.; Nielsen, T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst., 2009, 101, 736-750.
20. Allred, D.C.; Brown, P.; Medina, D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res., 2004, 6, 240-245.
21. Goldhirsch, A.; Ingle, J.N.; Gelber, R.D.; Coates, A.S.; Thürlimann, B.; Senn, H.J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol., 2009, 20, 1319-1329.
22. Aebi, S.; Davidson, T.; Gruber, G.; Cardoso, F; ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2011, 22 (Suppl 6), vi12-vi24.
23. Saphner, T.; Tormey, D.C.; Gray, R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol., 1996, 14, 2738-2746.
24. Dowsett, M.; Cuzick, J.; Wale, C.; Howell, T.; Houghton, J.; Baum, M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesisgenerating study. J. Clin. Oncol., 2005, 23, 7512-7517.
25. Budzar, A.U. Endocrine Therapies in Breast Cancer; Oxford University Press: New York, 2007.
26. Ibrahim, M.; Dodson, A.; Barnett, S.; Fish, D.; Jasani, B.; Miller, K. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am. J. Clin. Pathol., 2008, 129, 398-409.
27. Bedard, P.L.; Piccart-Gebhart, M.J. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. Curr. Opin. Oncol., 2009, 21, 491-498.
28. Hammond, M.E.H.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; Hicks, D.G.; Lester, S.; Love, R.; Mangu, P.B.; McShane, L.; Miller K.; Osborne, C.K.; Paik, S.; Perlmutter, J.; Rhodes A.; Sasano, H.; Schwartz, J.N.; Sweep, F.C.; Taube, S.; Torlakovic, E.E.; Valenstein, P.; Viale, G.; Visscher, D.; Wheeler, T.; Williams, R.B.; Wittliff, J.L.; Wolff, A.C. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol., 2010, 28, 2784-2795.
29. Dowsett, M.; Allred, C.; Knox, J.; Quinn, E.; Salter, J.; Wale, C.; Cuzick, J.; Houghton, J.; Williams, N.; Mallon, E.; Bishop, H.; Ellis, I.; Larsimont, D.; Sasano, H.; Carder, P.; Cussac, A.L.; Knox, F.; Speirs, V.; Forbes, J.; Buzdar, A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol., 2008, 26, 1059-1065.
30. Viale, G.; Regan, M.M.; Maiorano, E.; Mastropasqua, M.G.; Dell Orto, P.; Rasmussen, B.B.; Raffoul, J.; Neven, P.; Orosz, Z.; Braye, S.; Ohlschlegel, C.; Thürlimann, B.; Gelber, R.D.; Castiglione-Gertsch, M.; Price, K.N.; Goldhirsch, A.; Gusterson, B.A.; Coates, A.S. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol., 2007, 25, 3846-3852.
31. Jansen, M.P.; Foekens, J.A.; van Staveren, I.L.; Dirkzwager-Kiel, M.M.; Ritstier, K.; Look, M.P.; Meijer-van Gelder, M.E.; Sieuwerts, A.M.; Portengen, H.; Dorssers, L.C.; Klijn, J.G.; Berns, E.M. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol., 2005, 23, 732-740.
32. Sotiriou, C.; Wirapati, P.; Loi, S.; Harris, A.; Fox, S.; Smeds, J.; Nordgren, H.; Farmer, P.; Praz, V.; Haibe-Kains, B.; Desmedt, C.; Larsimont, D.; Cardoso, F.; Peterse, H.; Nuyten, D.; Buyse, M.; van de Vijver, M.J.; Bergh, J.; Piccart, M.; Delorenzi, M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst., 2006, 98, 262-272.
33. Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim W.; Cronin, M.; Baehner, F.L.; Watson, D.; Bryant, J.; Costantino, J.P.; Geyer, C.E. jr.; Wickerham, D.L.; Wolmark, N. Gene expression and benefit f chemotherapy in women withnode-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006, 24, 3726-3734.
34. National Comprehensive Cancer Network (NCCN) Guidelines, 2012: Available from: www.nccn.org.
35. Perez, E.A. Safety profiles of tamoxifen and aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann. Oncol., 2007, 18 Suppl 8, viii26-viii35.
36. Goldhirsch, A.; Gelber, R.D. Breast cancer: Anastrozole and fulvestrant-combination to unlock efficacy. Nat. Rev. Clin. Oncol., 2012, 9, 556-557.
37. Basso, U.; Fratino, L.; Brunello, A.; Lumachi, F.; De Salvo, G.L.; Lonardi, S.; Ghiotto, C.; Koussis, H.; Pasetto, L.M.; Monfardini, S. Which benefit from adding gemcitabine to vinorelbine in elderly (or=70 years) women with metastatic breast cancer? Early interruption of a phase II study. Ann. Oncol., 2007, 18, 58-63.
38. Beatson, G.T. On treatment of inoperable cases of carcinoma of the mamma: suggestions of a new method of treatment with illustrative cases. Lancet, 1896, 2, 104-107.
39. Puhalla, S.; Bhattachatya, S.; Davidson, N.E. Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. Mol. Oncol., 2012, 6, 222-236.
40. Miller, W.R. Biological rationale for endocrine therapy in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab., 2004, 18, 1-32.
41. Higgins, C.; Dao, T.L. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. JAMA, 1953, 151, 1388-1394.
42. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet, 1993, 341, 1293-1298.
43. Love, R.R.; Philips, J. Ooforectomy for breast cancer: History revisited. J. Natl. Cancer Inst., 2002, 94, 1433-1434.
44. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet, 1996, 348, 1189-1196.
45. Neill, A.; Price, K.N.; Goldhirsch, A.; Coates, A.S.; Colleoni, M.; Nasi, M.L.; Bonetti, M.; Gelber, R.D. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J. Natl . Cancer Inst., 2003, 95, 1833-1846.
46. Baum, M.; Hackshaw, A.; Houghton, J.; Rutqvist, L.E.; Fornander, T.; Nordenskjold, B.; Nicolucci, A.; Sainsbury, R. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur. J. Cancer, 2006, 42, 895-904.
47. Kaufmann, M.; Graf, E.; Jonat, W.; Eiermann, W.; Vescia, S.; Geberth, M.; Conrad, B.; Gademann, G.; Albert, U.S.; Loibl, S.; von Minckwitz, G.; Schumacher, M. A randomised trial of goserelin versus control after adjuvant, risk-Adapted chemotherapy in premenopausal patients with primary breast cancer -GABG-IV B-93. Eur. J. Cancer, 2007, 43, 2351-2358.
48. Schmid, P.; Untch, M.; Kossé, V.; Bondar, G.; Vassiljev, L.; Tarutinov, V.; Lehmann, U.; Maubach, L.; Meurer, J.; Wallwiener, D.; Possinger, K. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J. Clin. Oncol., 2007, 25, 2509-2515.
49. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365, 1687-1717.
50. Kaufmann, M.; Jonat, W.; Blamey, R.; Cuzick, J.; Namer, M.; Fogelman, I.; de Haes, J.C.; Schumacher, M.; Sauerbrei, W. Survival analyses from the ZEBRA study: goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur. J. Cancer., 2003, 39, 711-717.
51. Arriagada, R.; Lě, M.G.; Spielmann, M.; Mauriac, L.; Bonneterre, J.; Namer, M.; Delozier, T.; Hill, C.; Tursz ,T. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann. Oncol., 2005, 16, 389-996.
52. Griggs, J.J.; Somerfield, M.R.; Anderson, H.; Henry, N.L.; Hudis, C.A.; Khatcheressian, J.L.; Partridge, A.H.; Prestrud, A.A.; Davidson, N.E. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J. Clin. Oncol., 2011, 29, 3939-3942.
53. Osborne, C.K.; Zhao, H.; Fuqua, S.A. Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol., 2000, 18, 3172-3186.
54. Jordan, V.C. The past, present, and future of selective estrogen receptor modulation. Ann. N. Y. Acad. Sci., 2001, 949, 72-79.
55. Perez, E.A. Safety profiles of tamoxifen and aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann. Oncol., 2007, 18 Suppl 8, viii26-viii35.
56. Lien, E.A.; Solheim, E.; Ueland, P.M. Distribution of tamoxifene and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 1991, 51: 4837-4844.
57. Borges, S.; Desta, Z.; Li, L.; Skaar, T.C.; Ward, B.A.; Nguyen, A.; Jin, Y.; Storniolo, A.M.; Nikoloff, D.M.; Wu, L.; Hillman, G.; Hayes, D.F.; Stearns, V.; Flockhart, D.A. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther., 2006, 80, 61-74.
58. Bernard. S.; Neville, K.A.; Nguyen, A.T.; Flockhart, D.A. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist, 2006, 11, 126-35.
59. Goetz, M.P.; Schaid, D.J.; Wickerham, D.L.; Safgren, S.; Mushiroda, T.; Kubo, M.; Batzler, A.; Costantino, J.P.; Vogel, V.G.; Paik, S.; Carlson, E.E.; Flockhart, D.A.; Wolmark, N.; Nakamura, Y.; Weinshilboum, R.M.; Ingle, J.N.; Ames, M.M. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin. Cancer Res., 2011, 17, 6944-6951.
60. Regan, M.M.; Leyland-Jones, B.; Bouzyk, M.; Pagani, O.; Tang, W.; Kammler, R.; Dell-Orto, P.; Biasi, M.O.; Thürlimann, B.; Lyng, M.B.; Ditzel, H.J.; Neven, P.; Debled, M.; Maibach, R.; Price, K.N.; Gelber, R.D.; Coates, A.S.; Goldhirsch, A.; Rae, J.M.; Viale, G. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J. Natl. Cancer Inst., 2012, 104, 441-451.
61. Ahern, T.P.; Pederson, L.; Cronin-Fentn, D.P.; Sørensen, H.T., Lash, T.L. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 2562-2564.
62. Rae, J.M.; Drury, S.; Hayes, D.F.; Stearbs, V.; Thibert, J.N.; Haynes, B.P.; Salter, J.; Sestak, I.; Cuzick, I.; Dowsett, M. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl. Cancer Inst., 2012, 104, 452-460.
63. International Breast Cancer Study Group, Colleoni, M.; Gelber, S.; Simoncini, E.; Pagani, O.; Gelber, R.D.; Price, K.N.; Castiglione-Gertsch, M.; Coates, A.S.; Goldhirsch, A. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Ann. Oncol., 2007, 18, 1177-1184.
64. Morales, L.; Canney, P.; Dyczka, J.; Rutgers, E.; Coleman, R.; Cufer, T.; Welnicka-Jaskiewicz, M.; Nortier, J.; Bogaerts, J.; Therasse, P.; Paridaens, R. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Eur. J. Cancer., 2007, 43, 331-340.
65. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormones receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-Analysis of randomized trials. Lancet, 2011, 379, 771-784.
66. Ahn, S.H.; Son, B.H.; Kim, S.W.; Kim, S.I.; Jeong, J.; Ko, S.S.; Han, W. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea-A report from the Korean Breast Cancer Society. J. Clin. Oncol., 2007, 25, 2360-2368.
67. Stewart, H.J.; Prescott, R.J.; Forrest, A.M.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J. Natl. Cancer Inst., 2001, 93, 456-462.
68. Fisher; B.; Dignam; J.; Bryant; J.; Wolmark; N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl. Cancer Inst., 2001, 93, 684-690.
69. Recker, R.R.; Kendler, D.; Recknor, C.P.; Rooney, T.W.; Lewiecki, E.M.; Utian, W.H.; Cauley, J.A.; Lorraine, J.; Qu Y.; Kulkarni, P.M.; Gaich, C.L.; Wong, M.; Plouffe ,L. Jr.; Stock, J.L. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone, 2007, 40, 843-851.
70. Buzdar, A.U. Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Adv. Stud. Med., 2006, 6, S984-S993.
71. Vogel, V.G.; Costantino, J.P.; Wickerham, D.L.; Cronin, W.M.; Cecchini, R.S.; Atkins, J.N.; Bevers, T.B.; Fehrenbacher, L.; Pajon, E.R.; Wade, J.L, 3rd.; Robidoux ,A.; Margolese, R.G.; James, J.; Runowicz, C.D.; Ganz, P.A.; Reis, S.E.; McCaskill-Stevens, W.; Ford, L.G.; Jordan, V.C.; Wolmark, N. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev. Res., 2010, 3, 696-706.
72. Barrett-Connor, E.; Mosca, L.; Collins, P.; Geiger, M.J.; Grady, D.; Kornitzer, M.; McNabb, M.A.; Wenger, N.K. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med., 2006, 355, 125-137.
73. Howell, S.J.; Johnston, S.R., Howell, A. The use of selective estrogen receptor modulators and selective estrogen receptor downregulators in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab., 2004, 18, 47-66.
74. Chia, S.; Gradishar, W. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. Breast, 2008, 17, S16-S21.
75. Kieser, K.J.; Kim, D.W.; Carlson, K.E.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A. Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). J. Med. Chem., 2010, 53, 3320-3329.
76. Wardell, S.E.; Marks, J.R.; McDonnell, D.P. The turnover of estrogen receptor-by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem. Pharmacol., 2011, 82, 122-130.
77. Osborne, C.K.; Pippen, J.; Jones, S.E.; Parker, L.M.; Ellis, M.; Come, S.; Gertler, S.Z.; May, J.T.; Burton, G.; Dimery, I.; Webster, A.; Morris, C.; Elledge, R.; Buzdar, A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol., 2002, 20, 3386-3395.
78. Howell, A.; Robertson, J.F.; Abram, P.; Lichinitser, M.R.; Elledge, R.; Bajetta, E.; Watanabe, T.; Morris, C.; Webster, A.; Dimery, I.; Osborne, C.K. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol., 2004, 22, 1605-1613.
79. Ikeda, H.; Taira, N.; Nogami, T.; Shien, K.; Okada, M.; Shien, T.; Doihara, H.; Miyoshi, S. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci., 2011, 102, 2038-2042.
80. McKeage, K.; Curran, M.P.; Plosker, G.L. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs, 2004, 64, 633-648.
81. Mehta, R.S.; Barlow, W.E.; Albain, K.S.; Vandenberg, T.A.; Dakhil, S.R.; Tirumali, N.R.; Lew, D.L.; Hayes, D.F.; Gralow, J.R.; Livingston, R.B.; Hortobagyi, G.N. Combination anastrozole and fulvestrant in metastatic breast cancer. N. Engl. J. Med., 2012, 367, 435-444.
82. Roop, R.P.; Ma, C.X. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future Oncol., 2012, 273-292.
83. Bjornstrom, L.; Sjoberg, M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol., 2005, 19, 833-842.
84. Osborne, C.K.; Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med., 2011, 62, 233-247.
85. Dowsett, M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer, 2001, 8, 191-195.
86. Knowlden, J.M.; Hutcheson, I.R.; Jones, H.E.; Madden, T.; Gee, J.M.; Harper, M.E.; Barrow, D.; Wakeling, A.E.; Nicholson, R.I. Elevated levels of epidermal growth factor receptor/c-ErbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 2003, 144, 1032-1044.
87. Britton, D.J.; Hutcheson, I.R.; Knowlden, J.M.; Barrow, D.; Giles, M.; McClelland, R.A.; Gee, J.M.; Nicholson, R.I. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat., 2006, 96, 131-146.
88. Pancholi, S.; Lykkesfeldt, A.E.; Hilmi, C.; Banerjee, S.; Leary, A.; Drury, S.; Johnston, S.; Dowsett, M.; Martin, L.A. ErbB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr. Relat. Cancer, 2008, 15, 985-1002.
89. Arpino, G.; Weiss, H.; Lee, A.V.; Schiff, R.; De Placido, S.; Osborne, C.K.; Elledge, R.M. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl. Cancer Inst., 2005, 97, 1254-1261.
90. Clarke, R.; Liu, M.C.; Bouker, K.B.; Gu, Z; Lee, R.Y.; Zhu, Y.; Skaar, T.C.; Gomez, B.; O. Brien, K.; Wang, Y.; Hilakivi-Clarke, L.A. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene, 2003, 22, 7316-7339.
91. Kim, C.; Tang, G.; Pogue-Geile, K.L.; Costantino, J.P.; Baehner, F.L.; Baker, J.; Cronin, M.T.; Watson, D.; Shak, S.; Bohn, O.L.; Fumagalli, D.; Taniyama, Y.; Lee, A.; Reilly, M.L.; Vogel, V.G.; McCaskill-Stevens, W.; Ford, L.G.; Geyer, C.E. Jr.; Wickerham, D.L.; Wolmark, N.; Paik, S. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J. Clin. Oncol., 2011, 29, 4160-4167.
92. O. Reilly, K.E.; Rojo. F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66, 1500-1508.
93. Fagan, D.H.; Uselman, R.R.; Sachdev, D.; Yee, D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res., 2012, 72, 3372-3380.
94. Barnett, C.M. Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Pharmacotherapy, 2012, 32, 383-396.
95. Baselga, J.; Campone, M.; Piccart, M.; Burris, H.A. 3rd.; Rugo, H.S.; Sahmoud, T.; Noguchi, S.; Gnant, M.; Pritchard, K.I.; Lebrun, F.; Beck, J.T.; Ito, Y.; Yardley, D.; Deleu, I.; Perez, A.; Bachelot, T.; Vittori, L.; Xu , Z.; Mukhopadhyay, P.; Lebwohl, D.; Hortobagyi, G.N. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N. Engl. J. Med., 2012, 366, 520-529.
96. Toda, K.; Terashima, M.; Kamamoto, T.; Sumimoto, H.; Yokoyama, Y.; Kuribayashi, I.; Mitsuuchi, Y.; Maeda, T.; Yamamoto, Y.; Sagara, Y. Structural and functional characterization of human aromatase p450 gene. Eur. J. Biochem., 1990; 193; 559-565.
97. Simpson, E.R.; Davis, S.R. Minireview: aromatase and the regulation of estrogen biosynthesis -some new perspectives. Endocrinology, 2001, 142, 4589-4594.
98. Bulun, S.E.; Chen, D.; Lu, M.; Zhao, H.; Cheng, Y.; Demura, M.; Yilmaz, B.; Martin, R.; Utsunomiya, H.; Thung, S.; Su, E.; Marsh, E.; Hakim, A.; Yin, P.; Ishikawa, H.; Amin, S.; Imir, G.; Gurates, B.; Attar, E.; Reierstad, S.; Inne,s J.; Lin, Z. Aromatase excess in cancers of breast, endometrium and ovary. J. Steroid Biochem. Mol. Biol., 2007, 106, 81-96.
99. Lumachi, F.; Basso, S.M.; Orlando, R. Cytokines, thyroid diseases and thyroid cancer. Cytokine, 2010, 50, 229-233.
100. Jiao, J.; Xiang, H.; Liao, Q. Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer. Curr. Med. Chem., 2010, 17, 3476-3487.
101. Milani, M.; Jha, G.; Potter, D.A. Anastrozole use in early stage breast cancer of post-menopausal women. Clin. Med. Ther., 2009, 1, 141-156.
102. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Pöstlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; Samonigg, H.; Tausch, C.; Eidtmann, H.; Steger, G.; Kwasny, W.; Dubsky, P.; Fridrik, M.; Fitzal, F.; Stierer, M.; Rücklinger, E.; Greil, R; ABCSG-12 Trial Investigators, Marth, C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med., 2009, 360, 679-691.
103. Masuda, N.; Sagara, Y.; Kinoshita, T.; Iwata, H.; Nakamura, S.; Yanagita, Y.; Nishimura, R.; Iwase, H.; Kamigaki, S.; Takei, H.; Noguchi, S. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol., 2012, 13, 345-352.
104. Merke, D. P; Keil, M.F.; Jones, J.V.; Fields, J.; Hill, S.; Cutler, G.B. jr. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab., 2000, 85, 1114-1120.
105. Jordan, V.C.; Brodie, A.M. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 2007, 72, 7-25.
106. Aguilar, J.A.; Martin, H.L.; McNaughton, F.L. Aminoglutethimide in the treatment of epilepsy. Can. Med. Assoc. J., 1961, 84, 374-376.
107. Graves, P.E.; Salhanick, H.A. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinology, 1979, 105, 52-72.
108. Aron, D.C.; Findling, J.W.; Tyrrell, J.B. Hypotalamus & Pituitary. In: Basic & Clinical Endocrinology; Greenspan, F.S.; Gardner, D.G., Eds. Lange Medical Books/McGraw-Hill: New York, 2001, pp. 100-162.
109. Budzar, A.U. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin. Cancer Res., 2003, 9, 468S-4672S.
110. Geisler, J.; Johannessen, D.C.; Anker, G.; Lønning, P.E. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. Eur. J. Cancer, 1996, 32A, 789-792.
111. Tominaga, T.; Adachi, I.; Sasaki, Y.; Tabei, T.; Ikeda, T.; Takatsuka, Y.; Toi, M.; Suwa, T.; Ohashi, Y. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann. Oncol., 2003, 14, 62-70.
112. Kaufmann, M.; Bajetta E.; Dirix LY.; Fein LE.; Jones SE.; Zilembo N.; Dugardyn JL.; Nasurdi C.; Mennel, R.G.; Cervek, J.; Fowst, C.; Polli, A.; di Salle, E.; Arkhipov, A.; Piscitelli, G.; Miller, L.L.; Massimini, G. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J. Clin. Oncol., 2000, 18, 1399-1411.
113. Rose, C.; Vtoraya, O.; Pluzanska, A.; Davidson, N.; Gershanovich, M.; Thomas, R.; Johnson, S.; Caicedo, J.J.; Gervasio, H.; Manikhas, G.; Ben Ayed, F.; Burdette-Radoux, S.; Chaudri-Ross, H.A.; Lang, R. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer, 2003, 39, 2318-2327.
114. Ellis, M.J.; Suman, V.J.; Hoog, J.; Lin, L.; Snider, J.; Prat, A.; Parker, J.S.; Luo, J.; DeSchryver, K.; Allred, D.C.; Esserman, L.J.; Unzeitig, G.W.; Margenthaler, J.; Babiera, G.V.; Marcom, P.K.; Guenther, J.M.; Watson, M.A.; Leitch, M.; Hunt, K.; Olson, J.A. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J. Clin. Oncol., 2011, 29, 2342-2349.
115. Mauri, D.; Pavlidis, N. ; Polyzos, N.P.; Ioannidis, J.P. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-Analysis. J. Natl. Cancer Inst., 2006, 98, 1285-1291.
116. Gibson, L.; Dawson, C.; Lawrence, D.; Bliss, J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst. Rev., 2009 Jan 24, (1), CD003370.
117. Burstein, H.J.; Prestrud, A.A.; Seidenfeld, J.; Anderson, H.; Buchholz, T.A.; Davidson, N.E.; Gelmon, K.E.; Giordano, S.H.; Hudis, C.A.; Malin, J.; Mamounas, E.P.; Rowden, D.; Solky, A.J.; Sowers, M.R.; Stearns, V.; Winer, E.P.; Somerfield, M.R.; Griggs, J.J. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol., 2010, 28, 3784-3796.
118. Dowsett, M.; Cuzick, J.; Ingle, J.; Coates, A.; Forbes, J.; Bliss, J.; Buyse, M.; Baum, M.; Buzdar, A.; Colleoni, M.; Coombes, C.; Snowdon, C.; Gnant, M.; Jakesz, R.; Kaufmann, M.; Boccardo, F.; Godwin, J.; Davies, C.; Peto, R. Meta-Analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol., 2010, 28, 509-518.
119. Amir, E.; Seruga, B.; Niraula, S.; Carlsson, L.; Ocana, A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-Analysis. J. Natl. Cancer Inst., 2011, 103, 1299-1309.
120. Barnadas, A.; Estévez, L.G.; Lluch-Hernández, A.; Rodriguez-Lescure, A.; Rodriguez-Sanchez, C.; Sanchez-Rovira, P. An overview of letrozole in postmenopausal women with hormoneresponsive breast cancer. Adv. Ther., 2011, 28, 1045-1058.
121. Visvanathan, K.; Lippman, S.M.; Hurley, P.; Temin, S. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol. Oncol., 2009, 115, 132-134.